0
Abstract: Poster Presentations |

CAN BETA-2 AGONISTS SUBSTITUTE INHALED CORTICOSTEROIDS IN STABLE PERSISTENT ASTHMA? FREE TO VIEW

Quibtiya K. Syed, MBBS*; Naveed N. Shah, MD; Arshad A. Bachh, MD; Rakesh Bhargava, MD; Zuber Ahmed, MD; Deepak K. Pandey, MD; Mohammad Shameem, MD; Khurshid A. Dar, MD
Author and Funding Information

Government Medical College, Srinagar, India


Chest


Chest. 2008;134(4_MeetingAbstracts):p94003. doi:10.1378/chest.134.4_MeetingAbstracts.p94003
Text Size: A A A
Published online

Abstract

PURPOSE:Long acting beta-2 agonists (LABAs) are prescribed for patients with persistent asthma and are sometimes used without inhaled corticosteroids (ICSs). However, no study supports their use as monotherapy instead of ICS. The aim of our study was to study the effectiveness of formoterol fumerate-a long acting beta-2 agonist as an alternative therapy to budesonide-an ICS in patients who were well controlled by ICS.

METHODS:A 20-week, randomised, single blind, controlled trial was conducted on 100 patients attending OPD of the Department of Tuberculosis and Chest Diseases at JNMCH, AMU, Aligarh from February 2004 to August 2007. The study group (n=50) were put on formoterol fumerate (12 micrograms twice daily) by MDI/DPI and control group (n=50) were continued on budesonide (400 micrograms twice daily). Patients were assessed at 2 weeks intervals for severity of symptoms, pulmonary function tests, exacerbations and sputum eosinophils. Patients developing exacerbation were discontinued from the trial and managed accordingly.

RESULTS:During the trial, no significant differences between the formoterol and budesonide groups were observed for conventional outcomes of clinical studies of asthma therapy-PEFR, FEV1 and night awakenings. However, formoterol group had more exacerbations than budesonide group [4/50(28%) vs 5/50(10%), p<0.01)] and a greater increase in mean eosinophils [-2% vs 4%, p<0.01)].

CONCLUSION:Patients with persistent asthma well controlled by low dose of budesonide cannot be switched to formoterol monotherapy without risk of loss of asthma control.

CLINICAL IMPLICATIONS:LABAs cannot substitute ICSs in the treatment of stable asthma.

DISCLOSURE:Quibtiya Syed, None.

Wednesday, October 29, 2008

1:00 PM - 2:15 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543